Search

Memorial Sloan Kettering and IBM have agreed to collaborate on the development of a powerful tool built upon IBM Watson to provide medical professionals with improved access to comprehensive cancer data and practices.

… Thursday, March 22, 2012 Memorial Sloan Kettering Cancer Center (MSKCC) and IBM (NYSE: IBM) have agreed to collaborate on the development of a powerful tool built upon IBM Watson in order to provide  medical professionals with improved access to current and comprehensive cancer data and practices. The

The United States Preventive Services Task Force released updated draft recommendations on colorectal cancer screening which, among other things, call for screening for the general population to begin at age 45.

… Tuesday, October 27, 2020 The United States Preventive Services Task Force released updated draft recommendations on colorectal cancer screening which, among other things, call for screening for the general population to begin at age 45.  Currently the recommendations for those at average risk for the

Recently developed targeted drugs used to treat lung cancer are only partially effective. Scientists now know why.

… Wednesday, January 8, 2020 Summary Scientists at Memorial Sloan Kettering have discovered why certain drugs used to treat lung cancer are only partially effective. The findings point to combination therapies that might overcome this limitation. Among cancer biologists, finding a drug that can target

近期开发的用于治疗肺癌的靶向药物只是部分有效。而如今科学家发现了其中的原因。

… Wednesday, January 8, 2020 总结 纪念斯隆凯特琳癌症中心的科学家发现了为什么某些用于治疗 肺癌 的药物只是部分有效。研究结果表明，联合疗法也许能克服这一局限性。 对于癌症生物学家而言，他们一直致力于找到一种能靶向 KRAS 蛋白的药物。 KRAS 是癌症中最常见的突变蛋白之一，但直到最近人们还认为它基本上是不可药物治疗的——近乎球形的结构使其成为一个非常光滑的靶点。但在过去的几年中，科学家已发现用于阻止一种特定 KRAS 突变（KRAS G12C）的方法。蛋白质在“启动”和“关闭”之间循环，产生细微的形状变化，使得被称为 KRAS G12C 抑制剂的药物能够与之结合并使其失效

Memorial Sloan Kettering Cancer Center announces the appointments of medical oncologist Anas Younes, surgical pathologist David S. Kimstra, surgeon Julio Garcia-Aguilar, and radiologist Wolfgang Weber.

… Tuesday, March 5, 2013 Memorial Sloan Kettering Cancer Center announces the following appointments: Anas Younes, MD , has been named Chief of the Lymphoma Service in the Division of Hematologic Oncology, Department of Medicine. An internationally recognized medical oncologist with more than two decades

Researchers clarify how the immune system activates an inflammatory defense against pathogens.

… Thursday, April 18, 2019 Summary Pyroptosis is a form of inflammatory cell death launched by protein complexes called inflammasomes. Scientists have identified how an inflammasome called NLRP1B activates pyroptosis in immune cells to defend against anthrax infection. This sheds light on an important

Meet Leslie Ballantyne, Vice President of HR Legal and Regulatory Affairs at Memorial Sloan Kettering.

… Friday, April 2, 2021 Leslie Ballantyne says Eleanor Roosevelt has inspired her both personally and professionally. “The breadth of her accomplishments and commitment to her causes is just astounding,” says MSK’s Vice President of HR Legal and Regulatory Affairs. “She was ahead of her time in being an

A two-drug combination may hold the key to overcoming resistance in an aggressive form of non-Hodgkin lymphoma.

… Friday, November 16, 2018 Summary A promising target in the treatment of diffuse large B cell lymphoma (DLBCL) is a protein called BCL2. Drugs that inhibit this protein have been disappointing so far. Researchers have now discovered why DLBCL often proves resistant to this treatment. They have shown

A new era in the treatment of MIBC is on the horizon, with the combination of enfortumab vedotin plus pembrolizumab poised to become the new standard of care in the perioperative treatment of cisplatin-ineligible or cisplatin-refusing patients. MSK’s David Aggen, MD, discusses this, and what new treatment approaches physicians and scientists at MSK are now testing.

… Thursday, November 13, 2025 A Q&A with  David Aggen, MD, PhD , MSK Genitourinary Medical Oncologist and Cellular Therapist A new era in the treatment of muscle-invasive bladder cancer (MIBC) is on the horizon, with the combination of enfortumab vedotin plus pembrolizumab poised to become the new standard

MSK doctors and scientists are leading the charge to find new and innovative ways to treat metastatic brain cancer.

… Friday, February 16, 2018 Summary As cancer is increasingly being brought under control in other parts of the body, there is a growing focus on treating tumors that spread to the brain. Metastatic brain cancer gets far less attention in the media than primary brain tumors , despite being at least ten